Fiche publication
Date publication
novembre 2023
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
,
Dr VINCENT Julie
,
Dr BENGRINE-LEFEVRE Leila
,
Dr FUMET Jean-David
Tous les auteurs :
Roussot N, Vincent J, Palmier R, Constantin G, Bengrine L, Fumet JD, Ghiringhelli F
Lien Pubmed
Résumé
Advanced biliary tract cancer (BTC) has a poor prognosis. Gemcitabine with platinum chemotherapy was the standard first-line chemotherapeutic regimen until the recent addition of anti-PD-1/PD-L1 antibodies. After disease progression, the only second-line chemotherapy that has demonstrated a survival benefit versus supportive care is FOLFOX (folinic acid, fluorouracil, and oxaliplatin), with a modest benefit. This study aimed to assess the efficacy and safety of second-line FOLFIRI (folinic acid, fluorouracil, and irinotecan) combined with bevacizumab for advanced BTC.
Mots clés
FOLFIRI, FOLFIRI plus bevacizumab, advanced biliary tract cancer, bevacizumab, biliary tract cancer, chemotherapy, metastatic biliary tract cancer, second-line
Référence
Front Oncol. 2023 11 30;13:1293670
